Comparing 2 vs 4 rounds of chemo-immunotherapy before surgery for head and neck cancer
Part of Cancer, Mouth & dental clinical trials.
This trial tests whether 2 or 4 cycles of pembrolizumab (immunotherapy) plus carboplatin and nab-paclitaxel (chemotherapy) before surgery works better for people with advanced head and neck cancer that can be removed. The goal is to see if fewer treatments are just as effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 65 years old.
- You have head and neck squamous cell carcinoma that can be surgically removed and is stage T3 or T4 with no lymph node involvement (N0).
- You have at least one measurable tumor on scans.
- You have not had any prior systemic treatment for advanced/metastatic disease, or if you had prior platinum-based chemo, it ended at least 6 months ago.
- You are in good overall health (ECOG score 0 or 1) and your organs (bone marrow, liver, kidneys, heart, thyroid) work well enough per lab tests.
- You are not pregnant, breastfeeding, and willing to use effective contraception during treatment and for 4–6 months after.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for people with advanced head and neck cancer who had good response to chemotherapy plus immunotherapy before surgery. It compares two different follow-up treatments: more immunotherapy or radiation therapy to help prevent cancer from coming back.
This trial looks at whether giving an immunotherapy drug (a PD-1 inhibitor) after surgery is better than giving radiation therapy for people with advanced head and neck cancer who had a complete response to chemotherapy and immunotherapy before surgery. The goal is to prevent the cancer from coming back.
This trial tests a combination of three drugs (tirelizumab, carboplatin, and a special form of paclitaxel) given before surgery to treat advanced head and neck cancer. The goal is to see if this treatment can shrink the tumor and improve outcomes.
This trial tests a new combination of an immunotherapy drug (adelbelimab) plus chemotherapy given before surgery for head and neck cancer. The goal is to see if this treatment can shrink tumors and improve outcomes for people with advanced but removable head and neck squamous cell carcinoma.
This Phase 2 study tests pembrolizumab (an immunotherapy medicine) together with induction chemotherapy before the main cancer treatment for stage III/IVA head and neck squamous cell cancer. It aims to improve how well the tumor responds and how long people can stay controlled.
This trial tests whether giving tislelizumab (an immunotherapy) with chemotherapy before surgery works better than surgery alone for people with head and neck cancer that has not spread to lymph nodes. It's for cancers that can be removed with surgery, and the goal is to see if the pre-surgery treatment improves outcomes.
Hear when a new HNSCC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.